Berlin, Germany- March, 2024- Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence (AI)-driven approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, and a global leader in using computational pathology to transform complex biomedical data into biology insights.
The partners will co-create a novel target identification platform that leverages Aignostics’ technology, proprietary multimodal patient cohorts, and Bayer’s deep expertise in discovering and developing novel oncology therapies. In addition, the collaboration will include the development of computational pathology algorithms powered by AI and machine learning (ML) that connect baseline pathology data, such as molecular tumor profiles, with clinical data, such as patient outcomes, to enable better patient identification, stratification, and selection for clinical trials.
Moreover, The goal of the multi-year research collaboration is to identify novel cancer targets with a strong disease link through AI models applied to multimodal patient data and to accelerate clinical development of oncology programs. This approach can potentially address some of the challenges currently experienced in target discovery and disease heterogeneity.
“Gaining insights into human disease biology, discovering targets with a strong disease link by integrating artificial intelligence, machine learning and multimodal pathology into precision drug development has a huge potential for our R&D innovation strategy,” said Christian Rommel, Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of Research and Development.
The collaboration will leverage Aignostics’ technology and access to longitudinal, multimodal clinical data sets in well-characterized patient cohorts to discover new oncology targets for high unmet medical need indications. The companies, under the agreement terms, will collaborate on multiple discovery programs and will initiate at least two target identification programs.
Also Read: AI in Medicine: Challenges, Myths and the Future
“Innovation at Aignostics has always been fueled by close collaboration with clinicians and biopharma. With this partnership, we’re thrilled to take that approach to the next level. Fusing our technology and multimodal data with Bayer’s extensive expertise in drug discovery and clinical development has the potential to generate better drugs for patients with high unmet need in less time. Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare,” said Viktor Matyas, CEO of Aignostics GmbH.
